Lexaria delisted on the Canadian Stock Exchange and retained its listing on NASDAQ where traders and algos have had two runs at the share price. The company is looking at trading records however, having 53.5 million shares trade when there are only 5.1 million shares outstanding suggests some trading shenanigans.
It is one thing to have a drug which shows activity against an infection, virus or disease, it is another to deliver that drug effectively. Lexaria (NASDAQ:LEXX) is in the drug delivery business. Whether it is an anti-viral like COVID-19 focused Remdesivir and Ebastine or Cannabinoids including for Hypertension and Central Nervous System disorders, Lexaria’s DehydraTECH™ technology has the potential to enhance the performance of those drugs.